February
19
2020
Patient-reported outcomes from FLAURA: Osimertinib
versus erlotinib or gefitinib in patients with EGFRmutated
advanced non-small-cell lung cancer
February
19
2020
Management of common adverse events
related to first-line dacomitinib use in EGFR
mutation-positive non-small-cell lung cancer:
a pooled safety ana..
February
19
2020
Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or
erlotinib therapy in patients with lung cancer
February
19
2020
Pembrolizumab in Combination With Erlotinib or
Gefitinib as First-Line Therapy for Advanced
NSCLC With Sensitizing EGFR Mutation
February
19
2020
Expert Consensus on the Management of Adverse Events
from EGFR Tyrosine Kinase Inhibitors in the UK
February
19
2020
Advanced-Stage Non–Small Cell Lung Cancer:
Advances in Thoracic Oncology 2018
February
19
2020
Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal
growth factor receptor (EGFR) mutation-positive non-small cell lung cance..
February
19
2020
Relative efficacy of interventions in the
treatment of second-line non-small cell
lung cancer: a systematic review and
network meta-analysis
February
19
2020
FDA- and EMA-Approved Tyrosine Kinase Inhibitors
in Advanced EGFR-Mutated Non-Small Cell Lung
Cancer: Safety, Tolerability, Plasma Concentration
Mo..
February
19
2020
Randomized phase 3 open label study of quality of life of
patients on Pemetrexed versus Erlotinib as maintenance therapy
for advanced non squamous n..